Robotic surgery leader Intuitive Surgical (ISRG) is set to report second-quarter results after the market closes on July 16, with shares down more than 30% year-to-date. The central question is whether the release can act as the catalyst that reverses the prolonged sell-off.
The company arrives with a strong track record, having beaten analyst estimates in each of the past four quarters. Consensus forecasts call for revenue of $2.81 billion and earnings per share of $2.48. Another beat would likely lift the stock in the near term. More importantly, this year’s decline has compressed Intuitive’s forward price-to-earnings multiple to around 36 times, a steep discount to its five-year average of more than 58 times. That valuation reset alone creates room for an earnings-driven snapback.
The bull case rests heavily on the da Vinci 5 upgrade wave. Early data show hospital utilization of the next-generation system is roughly 11% higher than the legacy Xi platform. With customer adoption moving faster than anticipated, the accelerated trade-in cycle could deliver an upside surprise in both system placements and forward guidance. In the first quarter, the company installed 232 da Vinci 5 systems, compared with 147 in the same period last year. The platform introduces hardware-enabled artificial intelligence and Force Feedback technology, giving surgeons a physical sense of tissue resistance and pressure for the first time. This sets the technological baseline for the next decade and erects a barrier that newer competitors will struggle to replicate.
A second defensive layer is the highly recurring nature of revenue. More than 80% of the top line comes from instruments, accessories, and services. In the first quarter, this recurring stream grew 23% year over year to $2.12 billion, driven by roughly 16% growth in da Vinci procedure volume and a 39% jump in Ion procedure volume. Once a hospital installs a system, it is effectively locked into Intuitive’s ecosystem, generating sticky cash flow. The Ion robotic bronchoscopy platform is also pushing the company upstream from treatment into diagnosis and early intervention, with single-use consumables and the planned integration of endobronchial ultrasound lifting per-procedure revenue. Meanwhile, the single-port da Vinci SP system is gaining traction in urology and transoral otolaryngology.
Bears point to three concerns. GLP-1 obesity drugs have dampened bariatric surgery volumes, though that shortfall is being offset by growth in other procedure types. The recent move to extend Force Feedback instrument use from six to fifteen times could theoretically reduce repeat purchases, but Intuitive has expanded maximum use counts multiple times in the past with minimal impact on overall revenue—and the strategy tends to deepen customer loyalty. Finally, da Vinci 5 carries lower initial margins, and tariffs are adding to costs, meaning margin pressure may persist for several quarters.
Wall Street is not without optimists. Goldman Sachs analyst David Roman maintains a buy rating with a 12-month price target of $558, implying roughly 47% upside from the current level. He acknowledges that margin and tariff headwinds are unlikely to be fully resolved within six to twelve months, and betting on a nearly 50% gain over that window may be aggressive. Yet for investors with a multi-year horizon, the thesis remains intact: an underpenetrated addressable market, a wide moat built on steep switching costs, and rising demand linked to aging populations.
Tonight’s report will show whether the earnings serve as a pause button on the sell-off or the starting gun for a genuine recovery.
